Trinity Biotech PLC
IDA Business Park
Bray, Co
Wicklow
Tel: 353-1-276-9800-Or-800-603-8076
Fax: +353-1-276-9888
Website: http://www.trinitybiotech.com/
187 articles with Trinity Biotech PLC
-
Trinity Biotech Announces Fourth Quarter and Fiscal Year 2022 Financial Results
3/23/2023
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2022 and fiscal year 2022.
-
Trinity Biotech Welcomes TrinScreen HIV’s Inclusion In The New Kenyan HIV Testing Algorithm
3/22/2023
Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, welcomed the announcement by the Kenyan Ministry of Health of the adoption of a new HIV rapid testing algorithm.
-
Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2022 Financial Results
3/16/2023
Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2022 on Thursday, March 23, 2023.
-
Trinity Biotech Announces Entry Into An Increased Loan Facility to Fund Potential Acquisitions
2/22/2023
Trinity Biotech plc announced its entry into an increased loan facility to fund potential acquisitions and ongoing operations.
-
Trinity Biotech Announces Strategic Partnership with imaware™ to Deliver Integrated Diagnostic Testing Solutions to Digital Health Industry
1/9/2023
Trinity Biotech today announced a strategic partnership with imaware Inc that combines their built-to-partner digital health platform with Trinity Biotech’s advanced reference laboratory facilities to power the Digital Health Industry with at-home and remote testing programs.
-
Trinity Biotech Announces Q3 2022 Financial Results
12/15/2022
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended September 30, 2022.
-
Trinity Biotech plc to Announce Third Quarter Fiscal Year 2022 Financial Results
12/9/2022
Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter fiscal year 2022 on Thursday, December 15, 2022.
-
Trinity Biotech to participate in the Piper Sandler 34th Annual Healthcare Conference
11/30/2022
Trinity Biotech, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, is scheduled to participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022.
-
Trinity Biotech Announces Quarter 2 2022 Financial Results And Preliminary Q3 2022 Revenue Guidance
11/3/2022
Trinity Biotech plc announced the Company’s results for the quarter ended June 30, 2022 and preliminary guidance with respect to Q3 revenues.
-
Trinity Biotech plc to Announce Second Quarter Fiscal Year 2022 Financial ResultsConference Call Scheduled for November 3, 2022 at 11:00 am EASTERN
11/1/2022
Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2022 on Thursday, November 3, 2022.
-
Trinity Biotech Announces the Appointment of Tom Lindsay to its Board of Directors
10/26/2022
Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announces the appointment of Mr. Tom Lindsay to its Board of Directors as an independent non-executive director.
-
Trinity Biotech Announces The Appointment of Aris Kekedjian As Chairman and CEO
10/3/2022
Trinity Biotech plc today announced the appointment of Mr. Aris Kekedjian as CEO with effect from October 3, 2022.
-
Trinity Biotech Announces Results of AGM
9/30/2022
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the results of an Annual General Meeting (AGM).
-
Trinity Biotech plc to Announce First Quarter Fiscal Year 2022 Financial Results
6/29/2022
Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2022 on Thursday, June 30, 2022.
-
Trinity Biotech Announces CE Mark of its 10-Minute Covid-19 Antigen Test
5/20/2022
Trinity Biotech plc (Nasdaq: TRIB) has achieved a CE Mark for its 10-minute Covid-19 antigen test.
-
Trinity Biotech Announces the Successful Closing of its Strategic Investment and Partnership With The MiCo Group of South Korea
5/3/2022
Trinity Biotech plc announced that it has closed its recently announced strategic investment with the MiCo Group.
-
Australia’s Chimeric Therapeutics has partnered with WuXi ATU on two autologous CAR T-cell therapies for solid tumors. Switzerland-based CDR-Life closed a $76 million Series A.
-
Trinity Biotech Announces Quarter 4 and Fiscal Year 2021 Financial Results
4/11/2022
Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced results for the quarter ended December 31, 2021 and fiscal year 2021.
-
Trinity Biotech Announces A $45 Million Strategic Investment And Partnership With The MiCo Group of South Korea
4/11/2022
Trinity Biotech plc today announced a $45 million strategic investment and partnership with MiCo Ltd (“MiCo”). MiCo, a KOSDAQ-listed and Korea-based company, is engaged in the biomedical business through its affiliate MiCo BioMed, in addition to providing cutting-edge technology driven solutions in the semi-conductor and green energy sectors.
-
Biopharma and life sciences companies from across the globe provide updates to their pipelines and businesses.